Ustekinumab (Stelara®)

Reduce direct handling to a minimum and wear appropriate personal protective equipment.

Ustekinumab dosing is weight based; ensure accuracy of documented weight before administration

Caution High Administration Risk rating

Form & Storage	Each vial contains 130mg ustekinumab in 26mL (5mg/mL).	Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light
Reconstitution	Already in solution **MUST be further diluted before administration**	
Dose		

Body weight of patient	Recommended dose	No. of 130mg Stelara® vials	Volume of Stelara®
≤ 55kg	260mg	2	52mL
55kg to ≤ 85kg	390mg	3	78mL
>85kg	520mg	4	104mL

Compatibility & Stability	Sodium chloride 0.9%
Administration	**IV infusion** • Withdraw and discard a volume of the sodium chloride 0.9% solution from the 250 mL infusion bag equal to the volume of Stelara® to be added. • The final volume in the infusion bag should be 250 mL. Gently mix • Administer the diluted solution over a period of at least one hour. • Use only an infusion set with an **in-line filter** (pore size 0.2 micrometer). This filter **B Braun Sterifix® 0.2µ Ref 4099303** is available to order from stores
Monitoring	• Pre and post vital signs
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.
Adverse Drug Reactions	Monitor carefully during and for an hour after the infusion for hypersensitivity reactions.
Additional Information	STELARA® may increase the risk of infections and reactivation of latent infections. The first subcutaneous dose should be given at week 8 following the intravenous dose.

Information provided relates to Stelara® (Janssen-Cilag)